Intervention model for detection, prevention and control of COVID-19 in community pharmacy
DOI:
https://doi.org/10.1590/s2175-97902022e20988Keywords:
Intervention, Coronavirus, COVID-19, Minor ailments, Pharmaceutical careAbstract
The announcement by the WHO of the characterization of the new Coronavirus 2019 disease (COVID-19) as a pandemic, entails an adaptation by the community pharmacy in carrying out its care activity in general, with particular emphasis on ”Minor Ailments Service” in particular. The measures taken by the different health administrations in which patient telephone care by primary care offices is prioritized have left more consultations on symptoms in the community pharmacist health-related problems as pharmacies are the closest health facilities to the patient. The similarity between the symptomatology caused by the new Coronavirus with that of some Enteroviruses that cause mild respiratory and gastrointestinal tables (dry cough, fever, sore throat, vomiting, diarrhoea, etc.) makes community pharmacies highly capable places for contagion detection and prevention. A model of protocolized intervention is needed to facilitate the pharmacist’s work in discriminating during the indication between minor symptoms and symptoms of referral for possible cases of COVID-19 so that in conjunction with the rest of the staff we help control the disease and make better use of primary care consultations.
Downloads
References
Agomo CO. The role of community pharmacists in public health: a scoping review of the literature. J Pharm Health Serv Res. 2012;3(1):25-33.
Cheung KS, Hung IF, Chan PP, Lung KC, Tso E, Liu R, et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from the Hong Kong Cohort and systematic review and meta-analysis. Gastroenterology. 2020;S0016-5085(20)30448-0.
Chinese Pharmaceutical Association. CORONAVIRUS SARS-CoV-2 INFECTION: Expert Consensus on guidance and prevention strategies for hospital pharmacists and the pharmacy workforce (2nd edition) [EB/OL]. [Internet]. [Cited 2020 May 21]. Available from: Available from: http://www.cpa.org.cn/cpadmn/attached/file/20200216/1581854567839722.pdf
» http://www.cpa.org.cn/cpadmn/attached/file/20200216/1581854567839722.pdf
Fang Y, Huang TK, Yang SM. Research progress on pharmaceutical care provided in community pharmacies abroad. Chin Pharmaceut J. 2007;42(5):394-398.
Faus Dáder MJ, Amariles Múñoz P, Martínez Martínez F. Atención farmacéutica: conceptos, procesos y casos prácticos. Madrid: Ergón; 2008.
Gane SB, Kelly C, Hopkins C. Isolated sudden onset anosmia in COVID-19 infection. A novel syndrome? Rhinology. 2020;58(3):301.
Gong K, Xu Z, Cai Z, Chen Y, Wang Z. Internet hospitals help prevent and control the epidemic of COVID-19 in China: a multicenter user profiling study. J Med Internet Res. 2020;22(4):e18908.
Han Q, Lin Q, Jin S, You L. Recent insights into 2019-nCoV: a brief but comprehensive review. J Infect. 2020;80(4).
International Pharmaceutical Federation (FIP). CORONAVIRUS SARS-CoV-2 OUTBREAK: information and interim guidelines for pharmacists and the pharmacy workforce [EB/OL]. 2020a. [Cited 2020 May 21]. Available from: Available from: https://www.fip.org/file/4428
» https://www.fip.org/file/4428
International Pharmaceutical Federation (FIP) b. SRAS-CoV-2 outbreak preparedness. [Internet]. 2020b. [Cited 2020 May 21]. https://www.fip.org/coronavirus
» https://www.fip.org/coronavirus
Jurado MDMM, Herrera-Peco I, Pérez-Fuentes MDC, Gázquez Linares J. Análisis de la amenaza percibida por la COVID-19 en población española. Aten Primaria. 2020;52(7):515-516.
Kang JE, Rhie SJ. Practice Considerations on the Use of Investigational anti-COVID-19 Medications: Dosage, Administration and Monitoring. J Clin Pharm Ther. 2020;45(5):1199-1205.
Law S, Leung AW, Xu C. Severe acute respiratory syndrome (SARS) and coronavirus disease-2019 (COVID-19): From causes to preventions in Hong Kong. Int J Infect Dis. 2020;94:156-163.
Liu S, He G, Du J, Wang D, Shi C, Huang Q, et al. Pharmaceutical emergency guarantee difficulties and countermeasures for the prevention and control of outbreak of novel coronavirus pneumonia (NCP). Chin J Hosp Pharm. 2020a;40(3):243-9.
Liu S, Luo P, Tang M, Hu Q, Polidoro JP, Sun S, et al. Providing pharmacy services during the coronavirus pandemic. Int J Clin Pharm. 2020b;42(2):299-304.
Machuca M, Baena MI, Faus MJ. Guía de Indicación Farmacéutica IndDáder. Grupo de Investigación en Atención Farmacéutica (CTS-131) Universidad de Granada. ISBN: 84-689-4985-X. 2005. Available from: https://digibug.ugr.es/handle/10481/33049
» https://digibug.ugr.es/handle/10481/33049
National Health Commission of the People’s Republic of China. Diagnosis and treatment plan for patients with novel coronavirus pneumonia (6th trial version) [EB/OL]. [Internet]. [Cited 2020 May 21]. Available from: Available from: http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2/files/b218cfeb1bc54639af227f922bf6b817.pdf
Paudyal V, Hansford D, Cunningham S, Stewart D. Pharmacy assisted patient self care of minor ailments: a chronological review of UK health policy documents and key events 1997-2010. Health policy. 2011;101(3):253-9.
Si-qian Z, Li Y, Peng-xiang Z, Hui-bo L, Fang L, Rong-sheng Z. Recommendations and guidance for providing pharmaceutical care services during COVID-19 pandemic: A China perspective. Res Social Adm Pharm. 2021;17(1):1819-1824.
Tagarro A. Evolución de la pandemia por SARS COVID-19 en población pediátrica. Rev Esp Salud Publica. 2020.
Tresoldi I, Sangiuolo CF, Manzari V, Modesti A. SARS-COV-2 and infectivity. J Med Virol. 2020;92(10):1741-1742.
Ung COL. Community pharmacist in public health emergencies: quick to action against the coronavirus 2019-nCoV outbreak. Res Social Adm Pharm . 2020;16(4):583-586.
Wang L, He W, Yu X, Hu D, Bao M, Liu H, et al. Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up. J Infect . 2020a;80(6):639-645.
Wang X, Fang J, Zhu Y, Chen L, Ding F, Zhou R, et al. Clinical characteristics of non-critically ill patients with novel coronavirus infection (COVID-19) in a Fangcang Hospital, Clinical Microbiology and Infection. Clin Microbiol Infect. 2020b;S1198-743X(20)30177-4.
Wei M, Chen Q, Yu DM. The development of pharmaceutical care in domestic and foreign communities and its enlightenment on establishing pharmacy major in China. Chin Pharm J. 2010(12):98-100.
World Health Organization (WHO). Coronavirus Disease 2019 (COVID-19) Situation Report-52. [Internet]. 2020a. [Cited 2020 May21]. Available from: Available from: https://www.who.int/docs/default-source/coronaviruse/20200312-sitrep-52-covid-19.pdf?sfvrs n=e2bfc 9c0_2
» https://www.who.int/docs/default-source/coronaviruse/20200312-sitrep-52-covid-19.pdf?sfvrs n=e2bfc 9c0_2
World Health Organization (WHO). Coronavirus disease (COVID-19) pandemic [Internet]. 2020b. [Cited 2020 May 21]. Available from: Available from: https://www.who.int/es/emergencies/diseases/novel-coronavirus-2019
» https://www.who.int/es/emergencies/diseases/novel-coronavirus-2019
Xie M, Chen Q. Insight into 2019 novel coronavirus - an updated intrim review and lessons from SARS-CoV and MERS-CoV. Int J Infect Dis. 2020;94:119-124.
Yang Q, Xie L, Zhang W, Zhao L, Wu H, Jiang J, et al. Analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019. J Clin Pharm Ther . 2020;45(4):609-616.
Zhou T, Wei F. Primary stratification and identification of suspected Corona virus disease 2019 (COVID-19) from clinical perspective by a simple scoring proposal. Mil Med Res. 2020;7(1):16.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
